XML 13 R33.htm IDEA: XBRL DOCUMENT v2.4.1.9
New Products - Narrative (Details) (USD $)
3 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Dec. 31, 2014
Oct. 29, 2013
Apr. 30, 2015
Feb. 28, 2014
Business Acquisition [Line Items]            
Net revenues $ 8,686,774us-gaap_SalesRevenueNet $ 8,093,244us-gaap_SalesRevenueNet        
Upfront payments and milestone payments related to product sales 4,000,000cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales          
Omeclamox-Pak            
Business Acquisition [Line Items]            
Additional upfront payments       4,000,000cpix_BusinessCombinationAggregateUpfrontPayments
/ us-gaap_BusinessAcquisitionAxis
= cpix_OmeclamoxPakMember
   
Milestone payment     1,000,000cpix_ProductRIghtsAgreementMilestonePayment
/ us-gaap_BusinessAcquisitionAxis
= cpix_OmeclamoxPakMember
     
Vaprisol            
Business Acquisition [Line Items]            
Upfront payment           2,000,000cpix_BusinessCombinationUpfrontPayment
/ us-gaap_BusinessAcquisitionAxis
= cpix_VaprisolMember
Additional upfront payments           2,000,000cpix_BusinessCombinationAggregateUpfrontPayments
/ us-gaap_BusinessAcquisitionAxis
= cpix_VaprisolMember
Recognized gain on contingent consideration 400,000cpix_RecognizedGainLossonContingentConsideration
/ us-gaap_BusinessAcquisitionAxis
= cpix_VaprisolMember
         
Minimum | Omeclamox-Pak            
Business Acquisition [Line Items]            
Royalty payments based on percentage over gross profits       15.00%cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage
/ us-gaap_BusinessAcquisitionAxis
= cpix_OmeclamoxPakMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
   
Maximum | Omeclamox-Pak            
Business Acquisition [Line Items]            
Royalty payments based on percentage over gross profits       20.00%cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage
/ us-gaap_BusinessAcquisitionAxis
= cpix_OmeclamoxPakMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
   
Amended International Agreement | Pernix Therapeutics            
Business Acquisition [Line Items]            
Upfront payments and milestone payments related to product sales       4,000,000cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales
/ dei_LegalEntityAxis
= cpix_PernixTherapeuticsMember
/ us-gaap_TypeOfArrangementAxis
= cpix_AmendedInternationalAgreementMember
   
Omeclamox-Pak            
Business Acquisition [Line Items]            
Net revenues 758,191us-gaap_SalesRevenueNet
/ us-gaap_ProductOrServiceAxis
= cpix_OmeclamoxPakMember
1,139,421us-gaap_SalesRevenueNet
/ us-gaap_ProductOrServiceAxis
= cpix_OmeclamoxPakMember
       
Vaprisol            
Business Acquisition [Line Items]            
Net revenues 1,023,990us-gaap_SalesRevenueNet
/ us-gaap_ProductOrServiceAxis
= cpix_VaprisolMember
298,332us-gaap_SalesRevenueNet
/ us-gaap_ProductOrServiceAxis
= cpix_VaprisolMember
       
Subsequent Event | Vaprisol            
Business Acquisition [Line Items]            
Payments for contingent considerations         $ 1,600,000cpix_PaymentsforContingentConsideration
/ us-gaap_BusinessAcquisitionAxis
= cpix_VaprisolMember
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember